Related Experiment Video
Updated: May 13, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Interleukin 4 as a potential drug candidate for psoriasis
Christina Weigert1, Martin Röcken, Kamran Ghoreschi
1Eberhard Karls University Tübingen, University Medical Center, Department of Dermatology, Liebermeisterstrasse 25, 72076 Tübingen, Germany +49 7071 29 84555 ; +49 7071 29 4405 ; kamran.ghoreschi@med.uni-tuebingen.de.
Background:
Interleukin 4 (IL-4) is the central cytokine driving the differentiation of naive CD4(+) T helper (TH) cells into anti-inflammatory IL-4-producing TH2 cells. In contrast, IL-12/IL-23 promotes the development of TH1/TH17 immune responses that induce organ-specific autoimmune diseases such as psoriasis or multiple sclerosis.
Objective:
We focus on the potential of IL-4 and TH2 induction to treat inflammatory autoimmune diseases.
Methods:
Here, we summarize the basics for the establishment of the in vitro and in vivo conditions for the generation of TH2 immune responses, followed by various experimental data showing the therapeutic use of IL-4 for the therapy of autoimmune diseases. This data and early experiences with recombinant human IL-4 (rhIL-4) in the therapy of patients with cancer set the basis for the clinical introduction of rhIL-4 in the treatment of patients with psoriasis in a Phase I/II trial.
Conclusion:
IL-4 seems to act by inducing an anti-inflammatory phenotype and further clinical trials will explore the promising therapeutic potency of IL-4 in psoriasis during the upcoming era of biologics.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inhibitors of Viral Protein Synthesis